个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Lu, Shun[1,2] * ; Wang, Shubin[3] * ; Kim, Robert Y.[4] ; Zhang, Jiayu[3] ; Wang, Xianliang[1] ; Wang, Weidong[1,2] ; Zhu, Guiquan[1,2] ; Zhou, Jie[1] ; Tan, Yan[1] ; Tan, Mingyu[1] ; Li, Minglun[5] ; Yin, Gang[1,2] ; Li, Jie[1,2] ; Feng, Mei[1,2] ; Lang, Jinyi[1,2,*1] ;
机构： [1]Department of radiation oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [2]Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, China [3]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [4]Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A [5]Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany
出处：
DOI： 10.1111/1471-0528.17340
ISSN：

关键词： Cervical cancer applicator-guided IMRT boost intracavitary brachytherapy survival toxicity

摘要：
Objective: To investigate the clinical outcomes and toxicity in patients with locally advanced cervical cancer treated with supplementary applicator guided-intensity modulated radiation therapy (IMRT) based on conventional intracavitary brachytherapy (IC/IMRT). Design: A retrospective cohort study. Setting: Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, China. Population: Large high-risk clinical target volume (HR-CTV) volume (> 40 ml) at the time of brachytherapy cervical cancer patients were recruited. Methods: This study is a retrospective analysis of 76 patients with locally advanced cervical cancer (FIGO IIB-IVA) treated with concurrent chemoradiotherapy followed by IC/IMRT between June 2010 and October 2016. External radiotherapy (45 Gy in 25 fractions) was adminstered with cisplatin chemotherapy treatment before IC/IMRT. The IMRT plan was optimised using the ICBT plan base dose plan by an inverse dose optimisation tool which allows the use of DVH constraints on the total dose of ICBT. A seven-field gantry angle IMRT plan was devised to avoid hotspots when optimising the boost plan. The prescription dose for HR-CTV and IR-CTV were 6 and 5 Gy per fraction for five fractions, respectively. Results: Mean HR-CTV was 65.8 +/- 23.6 ml at the time of brachytherapy. D90 for HR-CTV and IR-CTV were 88.7 +/- 3.6 Gy and 78.1 +/- 2.5 Gy. D2cc for bladder, rectum, sigmoid and small intestine were 71.8 +/- 3.8, 64.6 +/- 4.9, 63.9 +/- 5.3 and 56.7 +/- 8.7 Gy, respectively. Median follow-up was 85 months (47.9-124.2 months). Five-year local recurrence-free survival rate, metastasis recurrence-free survival rate, disease-free survival rate and cancer-special survival rate were 87.6, 82.4, 70.9 and 76.3%, respectively. The grade 1 + 2 gastrointestinal and urinary late toxicities were 15.8 and 21.1%, and grade 3 late toxicities were 3.9 and 5.2%, respectively. Neither acute nor late grade 4 gastrointestinal or urinary toxicities were seen. Conclusions: The combination of ICBT with an applicator-guided supplementary IMRT boost achieved excellent local control and overall survival with low toxicity for bulky residual cervical tumour.

基金：
National Key Research and Development Program of China (grant number, 2017YFC0113100), and Key Research Project of Science and Technology Department of Sichuan Province (grant number, 2017SZ0013)
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 妇产科学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 妇产科学
JCR分区：
出版当年[2023]版：
Q1 OBSTETRICS & GYNECOLOGY
最新[2023]版：
Q1 OBSTETRICS & GYNECOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of radiation oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [2]Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of radiation oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [2]Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, China [*1]Department of radiation oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, China
推荐引用方式(GB/T 7714)：
Lu Shun,Wang Shubin,Kim Robert Y.,et al.Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour[J].BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY.2023,130(2):231-237.doi:10.1111/1471-0528.17340.
APA：
Lu, Shun,Wang, Shubin,Kim, Robert Y.,Zhang, Jiayu,Wang, Xianliang...&Lang, Jinyi.(2023).Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour.BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY,130,(2)
MLA：
Lu, Shun,et al."Clinical outcomes of conventional HDR intracavitary brachytherapy combined with complementary applicator-guided intensity modulated radiotherapy boost in patients with bulky cervical tumour".BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY 130..2(2023):231-237

相关文献

[1]Prognostic Factors for Toxicity and Survival in Advanced Cervical Cancer Patients Treated With High-Dose-Rate (HDR)-Intracavitary Brachytherapy (ICBT) Combined With Complementary Intensity Modulated Radiation Therapy (IMRT) [2]Treatment optimization with concurrent SBRT and intracavitary brachytherapy for locally advanced cervical cancer [3]Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer [4]Radiobiological and dosimetric comparison of 60Co versus 192Ir high-dose-rate intracavitary-interstitial brachytherapy for cervical cancer [5]Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique [6]Image Guided Radiation Therapy Boost in Combination With High-Dose-Rate Intracavitary Brachytherapy for the Treatment of Cervical Cancer [7]Phase 2 Trial for 3D HDR Intracavitary Brachytherapy Combined With Complementary Applicator-Guided External Beam Radiation Therapy for 338 Patients With Stage IIb-IIIb Uterine Cervical Cancer [8]Phase 2 Trial for 3D HDR Intracavitary Brachytherapy Combined With Complementary Applicator-Guided External Beam Radiation Therapy for 338 Patients With Stage IIb-IIIb Uterine Cervical Cancer [9]宫颈癌腔内联合组织间插植近距离治疗优化算法剂量学分析研究 [10]Analysis of Local Control Rate and Toxicity of Radiotherapy Dose of Cervical Cancer.

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号